Background Anandamide (AEA)-dependent signaling is regulated by the catabolic enzyme fatty acid amide hydrolase (FAAH). Several lines of evidence have demonstrated that FAAH and AEA are involved in the behavioral effects of alcohol. Therefore, we investigated whether a selective FAAH inhibitor, URB597 (cyclohexylcarbamic acid 3′-[aminocarbonyl]-[1,1′-biphenyl]-3-yl ester), altered alcohol intake in mice in a voluntary alcohol drinking model. Methods Mice, subjected to 3 weeks of chronic intermittent access (IA) in a two-bottle choice paradigm with 24-h access every other day, developed rapid escalation of alcohol intake and high preference. We evaluated the pharmacological effects of URB597 after both acute (1-day) withdrawal from chronic IA and 1-week withdrawal using the alcohol deprivation effect (ADE) model. AEA and N-acyl ethanolamide (NAE) abundances were determined after chronic IA, acute (1-day), or long-term (1 and 2 weeks) withdrawal in four brain regions.
Introduction
The endocannabinoid (eCB) system consists of cannabinoid receptors (CB1 and CB2) and endogenous cannabinoids (including anandamide [AEA] and 2-arachidonoyl glycerol). Pharmacological blockade of CB1 receptors reduces alcohol drinking in mice (Arnone et al. 1997) , decreases alcohol intake and the motivation to consume alcohol (Colombo et al. 1998; Gallate and McGregor 1999) , and blocks alcohol seeking in rats (McGregor et al. 2005) , suggesting that the eCB/ CB1 system is involved in the positive reinforcing properties and consumption of alcohol. In addition, mice lacking CB1 have reduced alcohol drinking or preference (Hungund et al. 2003; Wang et al. 2003; Naassila et al. 2004) , and alcoholinduced reward (Houchi et al. 2005) . Together, the increased eCB/CB1 activity is likely to promote alcohol intake during Yan Zhou and Benjamin I. Schwartz contributed equally to this work.
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early stages of alcohol drinking by potentiating acute alcohol reward (Manzanares et al. 1999) . In apparent contrast, eCB/ CB1 signaling deficiency occurs after chronic alcohol exposure and protracted withdrawal, which may promote alcohol intake through a negative reinforcement mechanism. Several findings support this notion: (1) down-regulation of CB1 expression and function is observed during protracted alcohol withdrawal (Mitrirattanakul et al. 2007; Varodayan et al. 2016) ; (2) in humans, in vivo imaging studies find decreased CB1 availability in heavy-drinking alcoholics that persists into abstinence (Hirvonen et al. 2013; Ceccarini et al. 2014) ; and (3) alcohol-dependent patients have lowered AEA levels in plasma during recent abstinence (Mangieri et al., 2009) .
The AEA-dependent signaling has been shown to be regulated by the enzyme involved in its catabolism, fatty acid amide hydrolase (FAAH) (Cravatt et al. 1996 (Cravatt et al. , 2001 . Several lines of evidence have demonstrated that AEA is involved in the behavioral effects of alcohol: inhibition or genetic deletion of FAAH, with resultant increases in AEA levels (Cravatt et al. 2001) , increases alcohol consumption and preference (Basavarajappa et al. 2006; Blednov et al. 2007 ). The FAAH C385A polymorphism (with increased eCB activity due to impaired FAAH function) has been reported to be associated with increased alcohol abuse and dependency (e.g., Sipe et al. 2002; Sloan et al. 2017) , and consistently, we found that the knock-in mice with the human FAAH C385A polymorphism had increased alcohol consumption (Zhou et al. 2016) , with decreased anxiety-like behavior (Dincheva et al. 2015) .
Withdrawal from alcohol is associated with increased stress responsivity and persistent negative affective symptoms, such as anxiety and depression, the severity of which are closely associated with alcohol relapse susceptibility (Koob and Kreek 2007) . eCBs exert prominent modulatory influence on the extended amygdala and corticostriatal circuits, and stress exposure disrupts eCB-enriched regions that participate in emotional control (Serrano et al. 2012; Dincheva et al. 2015; Morena et al. 2016) . Specifically, the relatively deficient eCB function is associated with increased anxiety and depression, and as such, impaired eCB activity may contribute to the negative affective states and increased stress responsivity that underlie negative reinforcement mechanisms driving alcohol drinking by dependent individuals and that contribute to alcohol relapse following periods of abstinence (Parsons and Hurd, 2015) . Pharmacologic and genetic manipulations (knockout or knock-in) of FAAH have been implicated in anxiolytic and anti-depressive behaviors (Bortolato et al. 2007; Gunduz-Cinar et al. 2013; Kathuria et al. 2003; Moreira et al. 2008; Carnevali et al. 2015) . However, there is no study on FAAH inhibitors in rodent models with alcohol withdrawal from high intake, though FAAH inhibition decreases anxiety-like behaviors that are present during alcohol withdrawal (Cippitelli et al. 2008 ).
Our hypothesis is that enhanced eCB signaling by FAAH inhibition opposes the effect of alcohol withdrawal driving alcohol escalation and Brelapse^drinking. In this study, therefore, we first investigated whether a selective FAAH inhibitor URB597 alters voluntary alcohol drinking in mice during acute (1 day) withdrawal from chronic (3-week) intermittent access (IA) alcohol drinking, to explore its potential for development as a therapeutic agent for alcoholism. In the IA model, the mice had access to alcohol drinking for 3 weeks in a two-bottle choice paradigm with alcohol drinking every other day, and the mice developed high alcohol consumption (15-25 g/kg/day). Thus, chronic IA mice constitute an appropriate animal model for studying voluntary alcohol drinking, as they display rapid escalation of high alcohol intakes (Hwa et al. 2011 ) and develop the alcohol deprivation effect (ADE, modeling the relapse episodes that occur in human alcoholics) (Zhou et al. 2017) . Consequently, we determined the pharmacological effects of URB597 in an ADE model, which allows for access to alcohol after 1 week of withdrawal. For comparison, we compared the effect of URB597 in the drinking-in-the-dark (DID) model, which allows for limited access (4 h/day) with low intake (<5-6 g/kg/day) (Rhodes et al. 2005) , and models Bbinge^drinking to the point of intoxication. Finally, we assessed the eCB system at a biochemical level in the IA model, by measuring relative abundances of AEA, other N-acyl ethanolamide (NAE) lipids and of FAAH protein after chronic IA and acute (1 day) or long-term (1 and 2 weeks) withdrawal, providing a dynamic profile of the eCB system in response to chronic alcohol IA consumption and subsequent withdrawal.
Material and methods

Animals
Male adult C57BL/6J (B6) mice (8 weeks of age) were obtained from The Jackson Laboratory (Bar Harbor, ME, USA) and housed in a temperature-controlled room (21°C). Mice were placed on a 12-h reverse light-dark cycle (lights off at 7:00 am) upon arrival and acclimated for a week prior to testing. During the first day of testing (i.e., session 1), all mice were 9 weeks of age. Mice were individually housed in ventilated cages fitted with steel lids and filter tops and given ad libitum access to food and water. Animal care and experimental procedures were conducted according to the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources Commission on Life Sciences 1996) and were approved by the Institutional Animal Care and Use Committee of the Rockefeller University.
Materials
FAAH inhibitor URB597 (cyclohexylcarbamic acid 3′-[aminocarbonyl]-[1,1′-biphenyl]-3-yl ester) and selective CB1 antagonist AM251 (Tocris Inc., Bristol, UK) were dissolved in 1% DMSO plus physiological saline and in 5% Cremophor in physiological saline, respectively. Alcohol solutions (7.5, 15, and 30% v/v) were prepared from 190 proof absolute ethyl alcohol (Pharmco-AAPER, Brookfield, CT, USA) and dissolved in tap water. Sucrose and saccharin (Sigma-Aldrich Inc., St. Louis, MO, USA) were diluted in tap water. Optima liquid chromatography-mass spectrometry (LC/MS) grade acetonitrile (Fisher Scientific, Pittsburgh, PA, USA) was used for metabolite extractions and liquid chromatography. Deuterated anandamide standard was purchased from Cayman Chemical (Ann Arbor, MI, USA).
Procedures
Chronic intermittent access
This model of alcohol drinking in C57BL/6J mice has been widely used for several years by many laboratories (e.g., Hwa et al. 2011; Zhou et al. 2017) (Table 1) .
The 3-week IA model Mice had access to alcohol drinking in their home cages for 3 weeks. Food and water were available at all times in this two-bottle choice paradigm with chronic alcohol exposure every other day. This IA model was similar to earlier protocols (e.g., Hwa et al. 2011) , with our modifications (Zhou et al. 2017) : At the time when the mice started individual housing (1 week before the experiments), the original water bottles were exchanged for those with sipper tubes to acclimate the mice to the sipper tubes (without ball bearings). Starting at 3 h after lights off (10:00 am), both the water and alcohol (7.5, 15, or 30%) solution sipper tubes were placed on their home cages. These sipper tubes were 10-ml pipettes that were cut at both ends, sealed with a rubber stopper, and fitted with a stainless steel straight sipper tubing. The sipper tubing contained a ball bearing at the end to prevent alcohol leakage. The left/right position of the tubes was randomly set to avoid the development of side preference. The alcohol pipettes were refilled with fresh alcohol solution and left for 24 h before being replaced with the water tubes. Alcohol solutions were prepared fresh every 48 h by mixing alcohol with tap water to reach the appropriate (v/v) alcohol concentration. Body weights were recorded every 2 days. Alcohol and water intake values were recorded after 4, 8, and 24 h of alcohol access in the drinking days (to the nearest 0.1 ml). These data were used to calculate consumed alcohol intake (i.e., g⁄kg) and relative preference for alcohol (i.e., alcohol intake/total fluid intake).
Mice exposed to the two-bottle Balcohol vs. water^choice regimen every other day rapidly acquired alcohol drinking behavior, and subsequently, daily alcohol intake rose to levels averaging approximately 15-20 g/kg/day after 3 weeks with 15% alcohol, with a high preference ratio above 0.8-0.9. This 3-week voluntary IA alcohol exposure was found to give rise to blood alcohol concentrations (BAC) around 0.50-0.63 mg/ ml, which were within the range required to produce specific psycho-pharmacological effects (Hwa et al. 2011; Zhou et al. 2017) .
The mice randomized as the vehicle-treated and drugtreated groups had matched body weight and similar alcohol intake 24 h before the test day. The drug dissolved in vehicle was administered by an experimenter, blinded to the treatments given to the experimental groups.
Single, acute administration in the 3-week IA model After 1 day of withdrawal, alcohol (7.5, 15, or 30% concentrations) was presented 30 min after a single injection of URB597 (0.125, 0.25, 0.5, or 1 mg/kg in 1% DMSO, i.p.) or vehicle, and then alcohol and water intake values were recorded ( Table 1 ). The URB597 doses chosen (0.125-1 mg/kg) were based on the literature (Blednov et al. 2007; Manwell et al. 2009) .
In this experiment, we also tested the effect of URB597 at 0.5 mg/kg after 1 day of withdrawal in female mice exposed to 3 weeks of IA. We did not observe any sex differences in the effects of URB597 after either single or repeated administration in the following experiments, suggesting that the estrous cycle and associated hormones might not be important factors in the response to these treatments in females.
Lastly, we used selective CB1R antagonist AM251 to pharmacologically block the CB1R to confirm that the URB597 effects were mediated via CB1R. Mice were pretreated with AM251 (0.1 mg/kg) in 5% Cremophor plus saline (i.p.) 30 min before one URB597 (0.5 mg/kg) or vehicle (1% DMSO) injection 30 min before the drinking test. The AM251 dose chosen (0.1 mg/kg) was based on our recent study (Zhou et al. 2016 ).
Chronic (3-week) drinking-in-the-dark
This model of alcohol drinking in C57BL/6J mice has been widely in use by many laboratories (e.g., Rhodes et al. 2005) . In this one-bottle paradigm, alcohol exposure was every day, and alcohol drinking was measured during 4 h of alcohol access. This chronic DID model was similar to earlier protocols (Rhodes et al. 2005) , with our modifications (Zhou et al. 2017) . The procedures were identical to the above IA with the following exceptions: Starting at 3 h after lights off (10:00 am), the water bottle was replaced with one 10-ml alcohol (15%) pipette and left for 4 h before being replaced with the water bottle. Alcohol intake values were recorded after 4 h of alcohol access every day (to the nearest 0.1 ml). These data were used to calculate alcohol intake (i.e., g/kg). After 3 weeks of DID, the mice assigned to the vehicle-treated and URB597-treated groups with matched body weight had similar 15% alcohol intake 1 day before the test day. The URB597 doses (0.25 and 0.5 mg/kg) were chosen based on the results of the above IA alcohol study. On the test day (20 h of withdrawal), alcohol (15% concentration) was presented 30 min after a single injection of URB597 or vehicle. Control groups: mice experienced DID for 3 weeks and received one vehicle injection (1% DMSO, i.p.) before the 4-h drinking test. Test groups: mice experienced DID for 3 weeks and received one URB597 injection (0.25 or 0.5 mg/kg in 1% DMSO, i.p.) before the test.
Sucrose (caloric reinforcer) and saccharin (non-caloric reinforcer) drinking With 0.5 mg/kg URB597 (the most effective dose tested for reducing alcohol intake), we further tested the specificity of the action of URB597 on alcohol intake using sucrose or saccharin drinking behavior after single, acute administration in alcohol-naïve mice or following the IA. The URB597 dose was chosen also based on the literature for sucrose drinking tests (0.1-1 mg/kg) (Bortolato et al. 2007; Rademacher and Hillard, 2007) . The sucrose or saccharin preference test in mice is sensitive to the function of brain rewarding systems and is widely used to measure the expression of anhedonia after chronic stress (Lim et al. 2012 ) and during alcohol abstinence (Pang et al. 2013 ). In the following experiments, 15% alcohol IA exposure was identical to those in the above experiment as described in the BThe 3-week IA model^section. After 3 weeks of IA, the alcohol tube was switched to sucrose for three sessions with stable intakes. The mice assigned to the vehicle-treated or URB597-treated groups had similar sucrose intake 24 h before the test day. On the test day (after 8 days of alcohol withdrawal), sucrose (2 or 4%) and water intake values were recorded after 4, 8, and 24 h of sucrose access. In parallel separate experiments, saccharin drinking (0.1 or 0.2%) was tested after 3 weeks of IA with an identical procedure.
Single, acute administration of URB597 on sucrose or saccharin drinking after 3-week IA A single i.p. injection of URB597 (0.5 mg/kg) in 1% DMSO or vehicle was given 30 min before the sucrose and saccharin were presented. Mice were assigned to one of two treatment groups: vehicle as control and URB597.
Single, acute administration of URB597 on saccharin drinking in alcohol-naïve mice The procedures were identical to the above, except the mice were exposed to saccharin or sucrose only (after three training sessions).
The alcohol deprivation effect (ADE) after 1-week withdrawal from 3-week IA Similar to the above, mice were given access to 15% alcohol and water for 24 h and then received 24-h access to alcohol on alternating days for 3 weeks. In the baseline session, 15% alcohol and water intake values were recorded at 4, 8, and 24 h after 3 weeks of IA. The alcohol bottles were then removed from the cages leaving the mice with access to food and water ad libitum. After 7 days of withdrawal, the alcohol (30%) bottles were presented to the mice 3 h after the dark cycle and the alcohol and water intake values were recorded at 4, 8, and 24 h in the ADE session. In the following two experiments, we also tested the effect of URB597 at 0.5 mg/kg in female mice with the ADE model.
Single, acute administration in the ADE model The mice assigned to the vehicle-treated or URB597-treated groups had Repeated administration in the ADE model In the following experiments, alcohol exposure procedure was identical to the above experiment in the BSingle, acute administration in the ADE model^section, with the following exceptions: mice received five consecutive administrations of vehicle or URB597 (0.5 mg/kg) during the 1-week withdrawal. On the ADE test day, alcohol (15%) was presented 1 day after the last URB597 injection, and then alcohol and water intake values were recorded after 4, 8, and 24 h of alcohol access.
N-Acyl ethanolamide extraction for mass spectrometry quantification
Brain tissue collection and extraction Alcohol-exposed and control (water) male mice from the 3-week chronic IA model were sacrificed by decapitation in the following groups: no alcohol withdrawal (immediately following the last day of alcohol exposure), 1-day withdrawal, 1-week withdrawal, and 2-week withdrawal. Brain regions (nucleus accumbens [NAc] , prefrontal cortex [PFC], basolateral amygdala [BLA] , and cerebellum) were dissected and frozen on dry ice within 1 min of sacrifice. Brain regions from two mice were combined for each sample to ensure sufficient sample size. NAEs were extracted from brain tissue using a protocol adapted from a previously described method (Patel et al. 2003) : Stainless steel bead-beating beads were added to the Eppendorf tubes containing brain tissue. Four hundred microliters of acetonitrile (ACN) was added to the samples. One microliter of 1 ng/μl deuterated anandamide ([ 2 H 8 ]AEA) was added as an internal standard (IS). Bead-beating homogenization was performed using a TissueLyser II bead beater (Qiagen) for 1 min at 30/s frequency. Samples were maintained on dry ice until homogenization, after which they were kept on ice. Homogenates were centrifuged in a table top centrifuge cooled to 4°C at maximum speed for 10 min to pellet brain tissue. The supernatant was removed to a new Eppendorf and brain tissue was homogenized twice more in 400 μl ACN to ensure complete extraction of NAEs. Supernatants were combined and stored overnight at −20°C to precipitate particulates. Remaining brain tissue protein pellets were stored at −80°C until protein quantification. Brain extracts were centrifuged at max speed for 10 min and supernatants were removed to a new Eppendorf. Extracts were dried under a vacuum in a vacufuge, reconstituted in 500 μl ACN to remove metabolites from the side of the tube and dried again. Dried extracts were stored at −80°C until reconstitution for mass spectrometry.
Protein quantification Remaining protein pellets from brain tissue homogenization were dried under a vacuum in a vacufuge and dissolved in 0.2 N NaOH at 95°C and protein content was determined using standard Bio-Rad Bradford protein quantification protocol.
Liquid chromatography-mass spectrometry NAE quantification Dried brain extracts were reconstituted to the equivalent of 1 μl 70% ACN in water per 100 μg protein to correct for differences in brain tissue size. The relative abundances of NAEs were determined by liquid chromatographyelectrospray ionization mass spectrometry using a 1290 Infinity LC system (Agilent Technologies) coupled to a 6460 Triple Quadrupole Mass Spectrometer (Agilent Technologies). Metabolites were separated on a ZORBAX SB-Aq Rapid Resolution reversed-phase column (2.1 × 100 mm, 1.8 μm) using mobile phase A (deionized water, 1% ACN, 1 mM ammonium formate, 0.1% formic acid) and mobile phase B (ACN, 1% deionized water, 1 mM ammonium formate, 0.1% formic acid). Samples were eluted using the following gradient: 
MS data analysis
Western blot
Alcohol-exposed and control (water) male mice from the 3-week chronic IA model were sacrificed by decapitation in the following groups: water control, 1-day withdrawal, 1-week withdrawal, and 2-week withdrawal. Prefrontal cortex was dissected and frozen on dry ice within 1 min of sacrifice, and the tissues from two mice were combined for each sample to ensure sufficient sample size. Tissue lysates were prepared in lysis buffer containing 1% NP-40, 1% Triton, 10% Glycerol, 1% protease, and phosphatase inhibitors (Calbiochem, San Diego, USA) in 1× buffered saline on ice. Samples were triturated and spun down at 12,000 rpm for 10 min at 4°C. Supernatants were collected and protein concentration measured by Bradford (Bio-Rad, Hercules, USA). Proteins were resolved by SDS-PAGE electrophoresis using ready NuPAGE 10% Bis-Tris gel (Invitrogen, Carlsbad, USA) and probed as previously described (Dincheva et al. 2015) using anti-FAAH (1:500). Secondary HRP-conjugated antibodies were used at 1:3000 (Santa Cruz, Dallas, USA).
Data analysis
We performed power analyses to determine the number of mice required to provide statistically significant results, based on the levels of differences seen previously (Zhou et al. 2016 (Zhou et al. , 2017 , and predicted that these studies require six to eight animals per group. In the experiments with URB597, alcohol intake, water intake, total fluid, and preference ratio differences between the different groups were analyzed using two-way ANOVA with repeat measures for treatment (vehicle vs. drug) and for time (0-4, 5-8, vs. 9-24 h interval) in each sex (Fig. 1) . For dose response analysis on URB597, group differences for alcohol intake and preference ratios at the 4-h recording time were analyzed using one-way ANOVA for treatments with different doses (Fig. 2) . In the experiments with URB597 with 7.5 and 30% alcohol, alcohol intake and preference ratio differences across the different groups were analyzed using two-way ANOVA for treatment (vehicle vs. drug) and for concentration (7.5% vs. 30%) ( Table 2 ). In the experiments with URB597 combination with AM251, alcohol intake and preference ratio differences across the different groups were analyzed using one-way ANOVA for different treatments (Table 3 ). In the experiments with URB597 with 0.2 and 0.4% saccharin, saccharin intake and preference ratio differences across the different groups were analyzed using two-way ANOVA for treatment (vehicle vs. drug) and for concentration (0.2 vs. 0.4%) (Fig. 3) . In the ADE experiments, alcohol intake differences across the different groups were analyzed using two-way ANOVA for treatment (vehicle vs. drug) and for session (baseline vs. ADE) in each sex, with testing our a priori hypothesis that there was an ADE based on the published findings (e.g., Vengeliene et al. 2014; Zhou et al. 2017) (Figs. 4 and 5) . For NAE quantification, abundance differences between water and alcohol groups were analyzed using a two-tailed Student's t test followed by Bonferroni post hoc tests (Fig. 6) or one-way ANOVA with different time points (Fig. 7) . All the ANOVA analysis was followed by Newman-Keuls post hoc tests. The accepted level of significance for all tests was p < 0.05. All statistical analyses were performed using Statistica (version 5.5, StatSoft Inc., Tulsa, OK).
Results
Single, acute administration of URB597 reduced alcohol (but not sucrose) intake and preference after 1 day of withdrawal from chronic IA Single, acute URB597 at 0.5 mg/kg reduced 15% alcohol intake and preference in male and female mice
In male mice, for intake, two-way ANOVA with repeat measure revealed a significant effect of URB597 treatment [F (1, 13) = 4.6, p < 0.05], and post hoc analysis showed that the URB597-treated males had less intake than the vehicle-treated ones at 4 h (p < 0.01) (Fig. 1a) . In comparison to the vehicle controls, 0.5 mg/kg URB597 reduced mean alcohol intake by 40-60% after 4 h, associated with a compensatory increase in water intake (resulting in virtually unchanged total fluid intake [ Table S1 ]). For preference ratio at this dose, two-way ANOVA with repeat measure revealed a significant interaction between URB597 treatment and time interval [F (1, 26) = 6.2, p < 0.01], and post hoc analysis showed that the URB597-treated males had less preference than the vehicle-treated ones at 4 h (p < 0.05) (Fig. 1b) .
In this experiment, we also tested the effect of URB597 at 0.5 mg/kg in female mice after 3 weeks of IA, and URB597 had a similar reducing effect on alcohol intake and preference. As no significant sex difference in the effects of URB597 was found (Table S2) , the female data are presented separately (Fig. 1c, d ). For intake, twoway ANOVA with repeat measure revealed a significant effect of URB597 treatment [F (1, 14) = 4.8, p < 0.05], and post hoc analysis showed that the URB597-treated females had less intake than the vehicle-treated ones at 4 h (p < 0.05) (Fig. 1c) . For preference ratio, two-way ANOVA with repeat measure revealed a significant effect of URB597 treatment [F (1, 14) = 8.6, p < 0.05], and the URB597-treated females had less preference than the vehicle-treated ones at both 0-4 and 5-8 h intervals (p < 0.01 for both, post hoc analysis) (Fig. 1d) .
Dose response of URB597 in male mice
At the 4-h time point, the full dose response of single, acute URB597 administration (0, 0.125, 0.25, 0.5, and 1 mg/kg) in terms of 15% alcohol intake and preference is presented in Fig. 2 . For intake (Fig. 2a) , one-way ANOVA revealed a 125-1 mg/kg) on reducing 15% alcohol intake (a) and preference ratio (b) in male mice (n = 6-7) after 1 day of withdrawal from 3-week chronic intermittent access alcohol drinking. Data were collected at the 4-h time point on the testing day and are expressed as a percentage of alcohol intake in vehicle-treated mice. *p < 0.05 or **p < 0.01 vs. control (URB597 at 0 mg/kg), and +p < 0.05 vs. 0.125 or 0.25 dose significant effect of URB597 [F (4, 28) = 9.6, p < 0.001], and post hoc analysis showed that (1) in comparison with the vehicle group, the URB597-treated males had less intake than the vehicle-treated ones at 0.25, 0.5, and 1.0 mg/kg doses (p < 0.05, p < 0.01, and p < 0.05, respectively), and (2) the reductions at 0.5 mg/kg was greater than the one at 0.125 mg/ kg (p < 0.05). For preference ratio (Fig. 2b) , one-way ANOVA revealed a significant effect of URB597 [F (4, 28) = 5.4, p < 0.005], and post hoc analysis showed that (1) in comparison with the vehicle group, the URB597-treated males had less preference than the vehicle-treated ones at both 0.5 and 1.0 mg/kg doses (p < 0.01 and p < 0.05, respectively), and (2) the reduction at 0.5 mg/kg was greater than the one at 0.125 and 0.25 mg/kg (p < 0.05 for both).
Single, acute URB597 (0.5 mg/kg) reduced 30% (but not 7.5%) alcohol intake and preference in male mice
For alcohol intake after 4 h ( Table 2) . Post hoc analysis showed that (1) the URB597-treated males had less intake than the vehicle-treated ones at 30% concentration (p < 0.01), and (2) without URB597 treatment, mice had more intake at 30% concentration than at 7.5% (p < 0.01). Pretreatment with selective CB1R antagonist AM251 (0.1 mg/kg) blocked the effect of acute URB597 (0.5 mg/kg) on reducing 15% alcohol drinking in male mice
One-way ANOVA revealed a significant effect of URB597 treatment [F (3, 23) = 5.1, p < 0.01], and post hoc analysis showed that the URB597-treated males had less intake than the vehicle-treated ones (p < 0.05). Although pretreatment with AM251 at 0.1 mg/kg alone had no effect on alcohol drinking per se, it blunted the effect of URB597 at 0.5 mg/ kg on alcohol drinking during 4 h (p < 0.05) ( Table 3) . For preference ratio, one-way ANOVA revealed a significant effect of URB597 treatment [F (3, 23) = 5.2, p < 0.01], and post hoc analysis showed that (1) the URB597-treated males had less preference than the vehicle-treated ones (p < 0.05), and (2) although pretreatment with AM251 at 0.1 mg/kg alone had no effect on preference ratio per se, it blunted the reducing effect of URB597 (p < 0.01).
No effects of single, acute URB597 (0.5 mg/kg) on sucrose intake and preference in male mice
As alcohol is a caloric reinforcer, the specificity of the action of URB597 on alcohol intake was tested after single, acute administration of 0.5 mg/kg URB597 on sucrose (caloric reinforcer) drinking in mice after chronic IA. In these experiments, the chronic 15% alcohol exposure procedures were identical to those in the above experiments. After 3 weeks of chronic IA, the alcohol tube was switched to sucrose for three sessions over 6 days, with stable intake observed. The male mice assigned to the vehicle-or URB597-treated groups had similar sucrose intake 24 h before the test day. URB597 had no significant effect on either intake or preference at 2 or 4% (Table 4) sucrose concentration. Further, in alcohol-naïve male mice (n = 6), there was no effect of 0.5 mg/kg URB597 on 4% sucrose intake (control mice 7.5 ± 0.77 g/kg; URB597 mice 7.7 ± 1.1 g/kg) or preference ratio (control 0.93 ± 0.05; URB597 0.96 ± 0.03).
Single, acute URB597 (0.5 mg/kg) increased saccharin preference ratio, but not intake in male mice
The specificity of the action of URB597 on alcohol intake was further tested on saccharin (non-caloric reinforcer) intake in mice. Like the sucrose experiments, after 3 weeks of chronic IA, the alcohol tube was switched to saccharin for three sessions over 6 days, and after stable intake observed, the male mice assigned to the vehicle-treated or URB597-treated groups had similar saccharin intake 24 h before the test day.
For saccharin intake after 4 h (Fig. 3a) , two-way ANOVA revealed a significant effect of saccharin concentration [F (1, 20) = 86, p < 0.00005] only. Post hoc analysis showed that with or without URB597 treatment, mice had more intake at 0.2% concentration than at 0.1% (p < 0.01). For preference ratio (Fig. 3b) Effects of single, acute administration of URB597 (URB, 0.5 mg/kg) on alcohol intake in an alcohol deprivation effect (ADE) model at 4 h in male (a, n = 7) and female (b, n = 6-9) mice after 1 week of withdrawal from 3-week chronic intermittent access alcohol drinking. *p < 0.05 vs. control baseline, and +p < 0.05 vs. ADE hoc analysis showed that the URB597-treated mice had more preference than the control mice at both 0.1 and 0.2% concentrations (p < 0.05 for both). Furthermore, in alcohol-naïve male mice (n = 6), there was no effect of 0.5 mg/kg URB597 on 0.1% saccharin intake (control mice 0.15 ± 0.02 g/kg; URB597 mice 0.13 ± 0.03 g/kg) or preference ratio (control 0.95 ± 0.02; URB597 0.97 ± 0.02).
Effect of single, acute or repeated administration of URB597 on ADE in both male and female mice
Single, acute URB597
In the single dose URB597 experiment, we tested the effect of URB597 at 0.5 mg/kg in both male and female mice and found similar reducing effects on the ADE. As there were no significant sex differences in the effects of URB597, the data of each sex are presented separately (Fig. 4) . In males at 4 h (Fig. 4a) , two-way ANOVA revealed a significant effect of URB597 treatment [F (1, 24) = 4.6, p < 0.05], and a significant interaction between session and treatment [F (1, 24) = 4.5, p < 0.05], and post hoc analysis showed that the URB597-treated males had less intake than the vehicle-treated ones in the ADE session [p < 0.05]. To test our a priori hypothesis that there was an ADE, we included the post hoc result showing that in the vehicle-treated mice, the ADE was significant after 4 h (p < 0.05), though two-way ANOVA did not reveal any significant effect of session after 4 h (Fig. 4a ). There were no significant effects of ADE or acute URB597 after 8 or 24 h (data not shown).
In females at 4 h (Fig. 4b) , two-way ANOVA revealed a significant effect of session [F (1, 26) = 4.3, p < 0.05], and post hoc analysis showed that the females had more intake in the ADE session than the baseline (p < 0.05). Though overall treatment difference was not significant, post hoc analysis showed that the URB597-treated females had less intake than the vehicle-treated ones in the ADE session (p < 0.05) (Fig.  4b) . Similar to the male mice, there were no significant effects of ADE or acute URB597 treatment after 8 or 24 h in females (data not shown).
Repeated URB597
In the repeated URB597 experiment, we tested the effect of URB597 at 0.5 mg/kg in both male and female mice and found similar reducing effects on the ADE. As there were no significant sex differences in the effects of URB597, the data of each sex are presented separately (Fig. 5) .
In males at 4 h (Fig. 5a ), two-way ANOVA revealed a significant effect of URB597 treatment [F (1, 20) = 5.8, p < 0.05], and a significant interaction between session and treatment [F (1, 20) = 5.9, p < 0.05], and post hoc analysis showed that the URB597-treated males had less intake than the vehicle-treated ones in the ADE session (p < 0.05). To test our a priori hypothesis that there was an ADE, we included the post hoc result showing that in the vehicle-treated mice, the ADE was significant after 4 h (p < 0.05) (Fig. 5a ), though twoway ANOVA did not reveal any significant effect of session. There were no significant effects of ADE or repeated URB597 after 8 or 24 h (data not shown).
In females at 4 h (Fig. 5b) , two-way ANOVA revealed a significant effect of session [F (1, 26) = 15.1, p < 0.001] and post hoc analysis showed that the females had more intake in the ADE session than the baseline (p < 0.01). However, there was no significant effect of the repeated URB597 treatment after 8 or 24 h (data not shown).
Acute (1 day) alcohol withdrawal transiently caused global brain eCB system dysregulation in male mice
Acute (1 day) withdrawal
Relative NAE abundances were detected in four mouse brain regions from male mice subjected to the chronic IA model following 1 day alcohol withdrawal as well as from control (water) male mice. All four brain regions showed a significant increase in the NAEs (Fig. 6, S1 ). AEA levels were increased the greatest, with a 3.1-, 2.7-, 2.1-, and 1.9-fold increase in the NAc, BLA, cerebellum, and PFC, respectively (Fig. 6a) . Palmitoyl ethanolamide (PEA) and oleoyl ethanolamide (OEA) were similarly increased (Fig. 6a, b, S1 ), as were other NAEs (data not shown).
Chronic IA and long-term withdrawal
Relative NAE abundances were further detected in the BLA of mice subjected to the chronic IA model as well as from that of control (water) mice in three groups: immediately after 3 week IA and long-term (1-and 2-week) withdrawal. This was done in order to determine the following: (A) whether the increased NAEs after 1 day withdrawal were due to chronic alcohol drinking or due to acute withdrawal, and (B) if NAE elevation after acute withdrawal was a short-term response to withdrawal or whether it persisted. Neither of these groups showed changed NAE levels, indicating that NAE elevation was a transient response to acute withdrawal (Fig. 7a, S2 ). As presented as fold change of AEA (Fig. 7b) , one-way ANOVA revealed a significant effect of time [F (3, 20) = 109, p < 0.000001], and post hoc analysis showed that the 1-day (24 h) withdrawal had higher ADE levels than other time points examined (p < 0.0001).
FAAH levels in the prefrontal cortex after withdrawal from chronic IA in male mice Protein lysates prepared from the PFC of male mice were analyzed by Western blotting. No difference in FAAH levels Table 4 No effect of single, acute administration of URB 597 (URB, 0.5 mg/kg) on 2% (A) and 4% (B) sucrose intake and their preference ratio in male mice after 4 h of sucrose access A 2% sucrose Vehicle (n = 6) 0.5 mg/kg URB (n = 6) Intake, g/kg 1.69 ± 0.14 2.10 ± 0.26 Preference 0.89 ± 0.04 0.94 ± 0.02 B 4% sucrose Vehicle (n = 6) 0.5 mg/kg URB (n = 6) Intake, g/kg 7.10 ± 0.98 7.70 ± 0.70 Preference 0.94 ± 0.02 0.93 ± 0.02 was detected after acute (1 day) or long-term (1 and 2 weeks) withdrawal, as compared to the water control (Fig. 8 ).
Discussion
Our first objective in the present study was to investigate the potential of an FAAH inhibitor, URB597, in reducing alcohol consumption in mice after acute (1 day) withdrawal from chronic IA alcohol drinking. Single acute administration of URB597 (a long-lasting inhibitor) significantly reduced 15% alcohol intake in mice in a dose-dependent manner (0.125-1 mg/kg) (Fig. 2a) . The URB597-induced reduction of alcohol intake was coupled with a full compensatory increase in water intake, resulting in no change in total fluid intake (Table S1 ). This indicates the absence of non-specific sedative effects by this FAAH inhibitor. Consistently, URB597 (0.125-1 mg/kg) produced a dose-dependent reduction in alcohol preference (Fig. 2b) . In the present study, we further confirmed that URB597 reduced alcohol drinking in a CB1-dependent manner, as selective CB1 antagonist AM251 blocked the effects of URB597 (Table 3 ). It is unlikely that the effect of URB597 in reducing alcohol intake was secondary to a general suppression of appetitive (anhedonic effect) or consumption behaviors, since URB597 at 0.5 mg/kg did not decrease sucrose (caloric reinforcer) (Table 4) or saccharin (non-caloric reinforcer) (Fig. 3) intake. The present study also found a relatively long duration (4 h) of the effect of single acute URB597 administration on alcohol drinking, which is likely due to its long-lasting bioactivity in vivo (Fegley et al. 2005; Basavarajappa et al. 2014) . Together, these results clearly demonstrate that the URB597-induced inhibition of FAAH plays a role in modulating alcohol drinking in mice.
Therefore, the development of FAAH inhibitors with improved pharmacokinetics has the potential to yield useful compounds for the treatment of alcoholism and other drug addictions (Panlilio et al. 2013; Zhou and Kreek 2014) . Though URB597 does not produce any reward (Gobbi et al. 2005) , repeated administration of URB597 has been found to correct the reduction in sucrose intake after chronic stress in both mice (Rademacher and Hillard, 2007) and rats (Bortolato et al. 2007 ). Our results showed that single acute URB597 administration at 0.5 mg/kg (the most effective dose tested for reducing alcohol intake) had no effect on sucrose or saccharin preference in alcohol-naïve mice, but increased saccharin preference in mice after 1-week alcohol withdrawal (Fig. 3) . Consistently, previous work has found that URB597 does not affect saccharin or sucrose drinking in stress-naïve animals (not rewarding) (Basavarajappa et al. 2006; Blednov et al. 2007; Manwell et al. 2009 ), but increases sucrose preference and/or intake in stress exposed animals due to Banti-depression^properties (Rademacher and Hillard, 2007; Bortolato et al. 2007 ). Together, our data suggest that the enhanced eCB activity resulting from the FAAH inhibitor can modulate sensitivity to saccharin reward during alcohol withdrawal. Alternatively, URB597 as an indirect eCB agonist may increase preference for more palatable reinforcers, such as saccharin (Fig. 3) and sucrose (slight, but not significant, increases at 2% [ Table 4 ]), with decreased preferences for less palatable reinforcers (15 and 30% alcohol), though URB597 itself is not rewarding (Gobbi et al. 2005) .
With low alcohol intake models, previous studies tested the FAAH inhibitor URB597 on alcohol-related behaviors: (1) on reinstatements of alcohol-seeking behavior, no effect was found after acute URB597 administration in rats with alcohol intake <2 g/kg during 1 h of alcohol access (Cippitelli et al. Fig. 8 No FAAH changes in male mice (n = 6) after acute or long-term withdrawal from 3-week chronic intermittent access (IA) alcohol drinking. A Western blot of FAAH at each time point and the corresponding intensity are shown. Control mice were given only water. Test mice were exposed to chronic IA alcohol (15%) drinking for 3 weeks and then 1 day, 1 week, or 2 week of withdrawal 2008), and (2) URB597 was reported to increase alcohol drinking in mice with alcohol intake <4 g/kg/day during 24 h of alcohol access (Blednov et al. 2007) . In contrast to mice in the 4-h limited-access DID paradigm, which had low alcohol intake (<5-6 g/kg/day) (Rhodes et al. 2005) , mice in the chronic IA paradigm showed Bheavy^drinking with 15-20 g/kg/day in males and 20-25 g/kg/day in females (Hwa et al. 2011; Zhou et al. 2017) . For these reasons, we purposely compared the effects of URB597 on chronic IA with DID and found that single acute URB597 administration at 0.5 mg/kg reduced alcohol drinking after 1 day withdrawal from chronic IA (Fig. 2) , with no effect after 1 day withdrawal from chronic DID (SI section, Results S1). When tested in other alcohol concentrations, we observed that single acute administration of URB597 at 0.5 mg/kg reduced high levels of alcohol intake with 30% alcohol, but had no effect on low levels of alcohol intake with 7.5% alcohol (Table 2) , consistent with the above notion. Together, our results demonstrate that URB597 modulates alcohol drinking in mice with long-access and chronic exposure to high levels of alcohol intake, but not with either limited access (like DID) or low levels of alcohol intake at 7.5% concentration. In accord with previous research, our data further indicate that the protective role of the eCBs becomes effective as the withdrawal from Bheavy^alcohol drinking is pronounced (Morena et al. 2016) . Drug escalation to highlevel intake is widely considered a hallmark of the transition from alcohol abuse to drug dependence in humans. Thus, our preclinical study may provide new information about the medical potential of URB597 in the treatment of alcoholism.
Our second main objective was to investigate the potential of URB597 in reducing relapse-like drinking in mice after long-term withdrawal. The phenomenon of a transient increase in alcohol consumption after a period of imposed abstinence has been termed the alcohol deprivation effect (ADE). It can be regarded as an animal model of relapse behavior and craving with good predictive validity (Vengeliene et al. 2014) . In the present study, mice of both sexes displayed the ADE with increased alcohol intake after 1 week of withdrawal (Figs. 4 and 5) . In contrast, the mice pretreated with single acute URB597 administration at 0.5 mg/kg had a blunted ADE in both sexes (Fig. 4) , suggesting the involvement of FAAH activity in the relapse-like drinking behavior. This finding with alcohol would constitute an interesting extension to the anti-relapse properties of URB597 observed in cocaine- (Chauvet et al. 2014 ), nicotine- (Scherma et al. 2008) , or opiate-seeking behaviors (Manwell et al. 2009) . One concern about the use of URB597 is that its FAAH inhibitory activity after repeated administration could result in the development of tolerance. Therefore, we tested the effectiveness of the multiple-dosing regimen (five daily injections before the ADE during the 1-week withdrawal) to mimic the multiple-dosing treatment in the clinic. Like the effect of single acute URB597 administration at 0.5 mg/kg on reducing the ADE in both sexes (Fig. 4) , the repeated pretreatments of URB597 at the same dose during the withdrawal week efficiently prevented the ADE drinking in mice (Fig. 5) , showing no tolerance development after this multiple-dosing regimen. It is worth mentioning that the prevention of the ADE by this multiple-dosing regimen occurred with the last URB597 administration 1 day before alcohol reexposure ADE. Thus, our findings show promising in vivo data indicating that the long-lasting FAAH inhibitor URB597 may show therapeutic potential in alcoholism treatment models.
Previous lines of experimental evidence have suggested chronic alcohol-exposed rats and mice as an animal model of alcohol withdrawal-induced Banxiety^and Bdepression^. These emotional states, and the search for the anxiolyticand antidepressant-like effects of alcohol, might in turn contribute to promoting the high levels of alcohol intake and preference that characterize the escalation drinking observed in the present study in mice (Colombo et al. 1995; Koob and Volkow 2010) . The stress-response eCB system is critically involved in Banxiety^-related behaviors (Dincheva et al. 2015; Parsons and Hurd 2015; Pardini et al. 2012; Spagnolo et al. 2016) , and FAAH inhibition reverses enhanced anxiety-like behavior present during alcohol withdrawal (Cippitelli et al. 2008) . Our mouse escalation model suggests a role for FAAH activity in the alcohol withdrawal-induced tendency of mice towards Banxiety^-and Bdepression^-like states. Thus, the increased AEA/CB1 activity after URB597 administration, by inhibiting FAAH activity (Basavarajappa et al. 2014) , could be partially responsible for the anxiolytic action of the FAAH inhibitor and subsequent reduction in alcohol intake after acute withdrawal in both male and female mice (Fig.  1) . In support of this concept, CB1 knockout mice with higher Banxiety^-like behavior (Bowers and Ressler 2016) display higher alcohol consumption than the wild-type littermates during the first days (Racz et al. 2003) .
Therefore, we sought to determine the effects of chronic high alcohol intake and subsequent alcohol withdrawal on the eCB system at a molecular level to better understand the dynamic changes in different brain regions. We used a targeted mass spectrometry method to quantify the relative abundance of NAE family of eCBs in the NAc, BLA, PFC, and cerebellum of mice. Interestingly, after acute 1-day withdrawal from 3-week chronic IA alcohol drinking, all four brain regions showed significant increases in the AEA, OEA, and PEA, with the NAc and BLA displaying the largest changes (Fig. 6) . As previous studies showed alterations of AEA levels in the amygdala and other brain regions of rats after chronic alcohol or withdrawal (Rubio et al. 2008; Robinson et al. 2016; Henricks et al. 2017) , we further determined dynamic profiles of relative abundances of NAEs in the BLA following chronic IA drinking (no withdrawal) and after 1 and 2 weeks of alcohol withdrawal, all of which showed no change compared to control (Fig.  7a, S2) . Together, this indicates that global NAE dysregulation occurs as a response to acute alcohol withdrawal only. This transient increase may be due to decreased FAAH activity, as found in the rats after 1-day alcohol withdrawal (Serrano et al. 2012 ), but not the FAAH expression level as observed in the present study (Fig. 8) . To our knowledge, this is the first description of global NAE dysregulation, both in terms of multi-localization and number of endogenous substrates (AEA, OEA, and PEA), in response to acute alcohol withdrawal, and indicates that a strong eCB response may act as an important molecular coping mechanism in acute alcohol withdrawal, thereby allowing the mice to better cope with alcohol withdrawal stress. As a possible allostatic process, the AEA surges may be resultant from the absence of an AEA release during 1-day acute withdrawal. Indeed, a recent study has found that the AEA release in the rat nucleus accumbens is observed only after acute alcohol, but not chronic alcohol or chronic withdrawal (Ceccarini et al. 2013) , though other reports showed that acute alcohol decreases (Ferrer et al. 2007) or did not change AEA release in this region (Alvarez-Jaimes et al. 2009 ). AEA and other NAE elevations were detected at 1-day withdrawal, whereas behavioral responses to the FAAH inhibitor URB597 (inhibition of alcohol drinking) were apparent at both 1-day and 1-week withdrawal time points. With the available data, the best explanation of this phenomenon is that naturally or pharmacologically elevated NAEs are protective from alcohol withdrawal stress. Naturally, this response (observed in tissue content, but not release) occurs only transiently as an acute response to withdrawal and does not persist after a week. However, after 1 week of alcohol withdrawal, pharmacological elevation of NAEs with an FAAH inhibitor still provides the same anti-stress protection, leading to reduce Brelapse^drinking. As the role of eCBs is complicated by their involvement in modulation of alcohol escalation and Brelapse^drinking, two other possible explanations should be considered. The AEA changes in other brain regions rather than the four areas tested could be correlated to alcohol withdrawal. Alternatively, our data suggest that the CB1 binding and/or function, and the downstream effects of CB1 receptor signaling can be more involved in the behavioral effects of the FAAH inhibition. Further study to elucidate these findings is warranted. In summary, in line with previous studies on cocaine-, nicotine-, and opiate-seeking behavior (Panlilio et al. 2013) , our findings show initial, promising in vivo data indicating that pharmacological FAAH inhibition decreases alcohol escalation and Brelapse^drinking in mice.
